The 1.78 PEG ratio, the highest in the peer set alongside RPM, signals that the market is not paying for growth PPG has not yet demonstrated: prior income statement work showed TTM revenue expansion of only 0.2% despite roughly 4% prior-quarter organic growth, consistent with divestiture drag masking underlying momentum. The 11.3x EV/EBITDA versus Axalta's 9.6x suggests PPG retains a modest premium over the pure industrial coatings peer, arguably justified by its aerospace and refinish exposure, but the gap to SHW appears structural rather than a temporary dislocation. Given the 14.6x D/EBITDA reading in Q3 2026, which appears inflated relative to the 9.7x in Q2, investors should weigh whether the valuation discount compensates adequately for execution risk on the architectural divestiture.

The divergence between a stable gross margin band of 37.4%–42.1% over the last six quarters and a declining operating margin aligns with the prior finding that SG&A grew to $876 million on $4.4 billion of revenue, outpacing top-line recovery and compressing operating leverage. Net margin of 10.4% in Q3 2026 sits close to the historical trend but is flattered by non-operating items, given the prior observation that reported EPS of $2.02 accompanied only $478 million of operating income. The 4.2% free cash flow margin in the latest quarter, versus a 15.0% print in Q4 2025, indicates that reported earning power is not currently converting into cash, so operating margin rather than net margin should anchor any normalization exercise.

ROE prints in the mid-teens (16.5% in Q3 2026) versus a depressed ROIC, which typically indicates leverage amplification rather than operating superiority; this is consistent with D/E at 0.87–1.11 through most of the period. Asset turnover of only 0.28, with the caveat that Q3 2026's $22.5 billion-plus asset base and goodwill concentration may distort the denominator, suggests the capital deployed per revenue dollar is high relative to a business generating ~$13 billion of annual sales. If the architectural divestiture completes, ROIC mathematically improves through asset shrinkage rather than margin expansion, an important distinction investors should monitor when evaluating whether compounding has genuinely turned.

The coverage trend appears directionally consistent with the prior income statement finding of operating margin compression: even with lower absolute debt, thinner EBIT coverage narrows the cushion for covenant or refinancing comfort in a downside scenario. Coverage of 7.1x remains adequate in absolute terms for a BBB-category industrial, but the swing from the 1.18x print in Q4 2024 shows how sensitive the ratio is to one-off charges that depressed EBIT in that period. Given the pending architectural divestiture, proceeds could accelerate de-levering or be recycled into bolt-on M&A; the direction of that capital deployment warrants close scrutiny, since the prior balance sheet work showed goodwill already near 28% of total assets.

The unusually low CCC prints of 5-17 days in recent quarters appear driven by extended payables (DPO of 148-157 days) rather than receivables or inventory discipline, which suggests the company is financing operations through supplier terms; sustainability of that posture is a legitimate question in a supply-constrained chemicals environment. That interpretation coheres with the prior cash flow finding of working capital swings between a $465 million use in Q1 2026 and a $464 million source in Q3 2026, meaning the CCC metric is capturing timing artifacts more than structural improvement. Asset turnover of 0.18-0.28 confirms a capital-intensive model whose efficiency metrics should be read against the divestiture, which will mechanically change the denominator.